{
    "eid": "2-s2.0-84929518247",
    "title": "Treatment of venous thromboembolism in the era of non-vitamin K antagonist oral anticoagulants",
    "cover-date": "2015-01-01",
    "subject-areas": [
        {
            "$": "General Medicine",
            "@code": "2700"
        }
    ],
    "keywords": [
        "Non-vitamin K antagonist oral anticoagulants",
        "Treatment",
        "Venous thromboembolism"
    ],
    "authors": [
        "Noppacharn Uaprasert"
    ],
    "citedby-count": 1,
    "ref-count": 31,
    "ref-list": [
        "A Population-Based Perspective of the Hospital Incidence and Case-Fatality Rates of Deep Vein Thrombosis and Pulmonary Embolism: The Worcester DVT Study",
        "A prospective study of the incidence of deep\u2010vein thrombosis within a defined urban population",
        "Deep vein thrombosis and pulmonary embolism in two cohorts: The longitudinal investigation of thromboembolism etiology",
        "Epidemiology of first and recurrent venous thromboembolism: A population-based cohort study in patients without active cancer",
        "POSTOPERATIVE THROMBOSIS IN THAI WOMEN",
        "Deep Vein Thrombosis After Hip Surgery Among Thai",
        "Incidence of deep vein thrombosis in postoperative hip fracture patients in Phramongkutklao Hospital.",
        "The prevalence of thrombophilia and venous thromboembolism in total knee arthroplasty",
        "Risk factors for symptomatic venous thromboembolism in Thai hospitalised medical patients",
        "Antithrombotic therapy for VTE disease: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines",
        "Emergency hospitalizations for adverse drug events in older Americans",
        "Recent progress in anticoagulant therapy: Oral direct inhibitors of thrombin and factor Xa",
        "Update on antithrombotic therapy: New anticoagulants",
        "Advantages and limitations of the new anticoagulants",
        "Dabigatran versus warfarin in the treatment of acute venous thromboembolism",
        "Extended Use of dabigatran, warfarin, or placebo in venous thromboembolism",
        "Oral rivaroxaban for symptomatic venous thromboembolism",
        "Oral rivaroxaban for the treatment of symptomatic pulmonary embolism",
        "Oral apixaban for the treatment of acute venous thromboembolism",
        "Apixaban for extended treatment of venous thromboembolism",
        "Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism",
        "Dabigatran and postmarketing reports of bleeding",
        "Rates, management, and outcome of rivaroxaban bleeding in daily care: Results from the Dresden NOAC registry",
        "Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran",
        "Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor",
        "Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: A randomized, placebo-controlled, crossover study in healthy subjects",
        "Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates",
        "A specific antidote for dabigatran: Functional and structural characterization",
        "Measuring oral direct inhibitors of thrombin and factor Xa: A recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis",
        "Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants",
        "The laboratory and the direct oral anticoagulants"
    ],
    "affiliation": {
        "affiliation-city": "Bangkok",
        "affilname": "Faculty of Medicine, Chulalongkorn University",
        "affiliation-country": "Thailand"
    },
    "funding": []
}